Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Multi-center, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of Recombinant Fully Human Anti-PD-1 Monoclonal Antibody (GLS-010 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

NCT03972722 is registered in ClinicalTrials.gov with Guangzhou Gloria Biosciences Co., Ltd. as lead sponsor.

NCT NCT03972722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03972722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Multi-center, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of Recombinant Fully Human Anti-PD-1 Monoclonal Antibody (GLS-010 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
Lead sponsor
Guangzhou Gloria Biosciences Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
May 15, 2019
Completion date
May 15, 2023
Enrollment
89 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer